The anti-CD19 chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel did not improve event-free survival (EFS) compared with standard care in patients refractory or who had progressed following first-line therapy for aggressive B-cell non-Hodgkin’s lymphoma, results of the phase III BELINDA trial showed.
Using a wearable medical cuff device can facilitate the continuous monitoring of vital signs, physical activity, and complications in patients on intensive treatment regimens for aggressive haematologic malignancies, according to a recent study.
The vasodilator ifenprodil together with sorafenib has been identified as a new drug combination for hepatocellular carcinoma (HCC) treatment by researchers from the University of Hong Kong (HKU) using clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) screen.
Adding ibrutinib to obinutuzumab in the first-line setting sustains progression-free survival (PFS) benefit in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL), including patients with high-risk genomic features, according to the ﬁnal analysis of the iLLUMINATE* trial.
Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.
Supplementation with vitamin D, otherwise called sunshine vitamin, and calcium may help women with breast cancer protect against bone loss associated with aromatase inhibitors (AIs), suggests a 5-year follow-up study from Brazil.
People who consume more olive oil in their diet have a lower risk of death from any cause or specific causes including cardiovascular disease (CVD), cancer, neurodegenerative disease, or respiratory disease compared with those who hardly or never consume olive oil, according to a large US study.
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.